- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07686263
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
A Phase 3 Double-blind, Placebo-controlled Randomized Withdrawal Maintenance Trial of KarXT Treatment in Participants With Schizophrenia
The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: First line of the email MUST contain NCT # and Site #.
Undersøgelse Kontakt Backup
- Navn: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
- Telefonnummer: 855-907-3286
- E-mail: Clinical.Trials@bms.com
Studiesteder
-
-
-
Buenos Aires, Argentina, C1199ABB
- Trukket tilbage
- Local Institution - 0143
-
Córdoba, Argentina, 5000
- Ikke rekrutterer endnu
- Local Institution - 0002
-
Kontakt:
- Site 0002
-
Córdoba, Argentina, 5003
- Ikke rekrutterer endnu
- Local Institution - 0197
-
Kontakt:
- Site 0197
-
Santiago del Estero, Argentina, 4200
- Rekruttering
- Clinica El Jardin
-
Kontakt:
- Gaston Noriega, Site 0144
- Telefonnummer: +5493854027710
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, Argentina, 5800
- Trukket tilbage
- Local Institution - 0175
-
-
-
-
-
Novi Iskar, Bulgarien, 1282
- Ikke rekrutterer endnu
- Local Institution - 0191
-
Kontakt:
- Site 0191
-
-
-
-
Arkansas
-
Bentonville, Arkansas, Forenede Stater, 72712
- Rekruttering
- Pillar Clinical Research - Bentonville
-
Kontakt:
- Fayz Hudefi, Site 0154
- Telefonnummer: 479-367-2688
-
Little Rock, Arkansas, Forenede Stater, 72204
- Rekruttering
- Pillar Clinical Research- Little Rock
-
Kontakt:
- Leslie Smith, Site 0139
- Telefonnummer: 501-350-3285
-
Little Rock, Arkansas, Forenede Stater, 72211
- Ikke rekrutterer endnu
- Local Institution - 0021
-
Kontakt:
- Site 0021
-
Rogers, Arkansas, Forenede Stater, 72758
- Ikke rekrutterer endnu
- Local Institution - 0153
-
Kontakt:
- Site 0153
-
-
California
-
Anaheim, California, Forenede Stater, 92805
- Ikke rekrutterer endnu
- Local Institution - 0190
-
Kontakt:
- Site 0190
-
Bellflower, California, Forenede Stater, 90706
- Rekruttering
- Clinical Innovations, Inc. dba CITrials
-
Kontakt:
- Gerald Maguire, Site 0040
- Telefonnummer: 562-249-6956
-
Culver City, California, Forenede Stater, 90230
- Ikke rekrutterer endnu
- Local Institution - 0032
-
Kontakt:
- Site 0032
-
Garden Grove, California, Forenede Stater, 92845
- Rekruttering
- Collaborative Neuroscience Research, LLC
-
Kontakt:
- David Walling, Site 0037
- Telefonnummer: 714-799-7799
-
La Habra, California, Forenede Stater, 90631
- Ikke rekrutterer endnu
- Local Institution - 0068
-
Kontakt:
- Site 0068
-
Lemon Grove, California, Forenede Stater, 91945
- Ikke rekrutterer endnu
- Local Institution - 0128
-
Kontakt:
- Site 0128
-
Montclair, California, Forenede Stater, 91763
- Ikke rekrutterer endnu
- Local Institution - 0187
-
Kontakt:
- Site 0187
-
Orange, California, Forenede Stater, 92868
- Rekruttering
- NRC Research Institute
-
Kontakt:
- Tony Ortiz, Site 0151
- Telefonnummer: 714-289-1100
-
Pico Rivera, California, Forenede Stater, 90660
- Ikke rekrutterer endnu
- Local Institution - 0030
-
Kontakt:
- Site 0030
-
Redlands, California, Forenede Stater, 92373
- Ikke rekrutterer endnu
- Local Institution - 0185
-
Kontakt:
- Site 0185
-
Riverside, California, Forenede Stater, 92506
- Ikke rekrutterer endnu
- Local Institution - 0186
-
Kontakt:
- Site 0186
-
Torrance, California, Forenede Stater, 90504
- Ikke rekrutterer endnu
- Local Institution - 0193
-
Kontakt:
- Site 0193
-
-
Florida
-
Boynton Beach, Florida, Forenede Stater, 33426
- Rekruttering
- Health Synergy Clinical Research
-
Kontakt:
- Mohammad Nisar, Site 0044
- Telefonnummer: 786-831-7303
-
Hollywood, Florida, Forenede Stater, 33024
- Rekruttering
- Research Centers of America ( Hollywood )
-
Kontakt:
- Edwin Gomez, Site 0145
- Telefonnummer: 954-604-3900
-
Miami, Florida, Forenede Stater, 33135
- Trukket tilbage
- Local Institution - 0075
-
Miami Lakes, Florida, Forenede Stater, 33016
- Trukket tilbage
- Local Institution - 0054
-
Miami Springs, Florida, Forenede Stater, 33166
- Trukket tilbage
- Local Institution - 0134
-
Oakland Park, Florida, Forenede Stater, 33334
- Ikke rekrutterer endnu
- Local Institution - 0195
-
Kontakt:
- Site 0195
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30331
- Rekruttering
- Atlanta Center for Medical Research
-
Kontakt:
- Elyssa Barron, Site 0166
- Telefonnummer: 404-881-5800
-
Sandy Springs, Georgia, Forenede Stater, 30328
- Ikke rekrutterer endnu
- Local Institution - 0070
-
Kontakt:
- Site 0070
-
Savannah, Georgia, Forenede Stater, 31405
- Ikke rekrutterer endnu
- Local Institution - 0189
-
Kontakt:
- Site 0189
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60641
- Rekruttering
- Pillar Clinical Research -Chicago
-
Kontakt:
- Roueen Rafeyan, Site 0056
- Telefonnummer: 312-865-6336
-
Chicago, Illinois, Forenede Stater, 60640-5017
- Ikke rekrutterer endnu
- Local Institution - 0067
-
Kontakt:
- Site 0067
-
-
Maryland
-
Gaithersburg, Maryland, Forenede Stater, 20877
- Ikke rekrutterer endnu
- Local Institution - 0192
-
Kontakt:
- Site 0192
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45219
- Ikke rekrutterer endnu
- Local Institution - 0183
-
Kontakt:
- Site 0183
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73112
- Ikke rekrutterer endnu
- Local Institution - 0047
-
Kontakt:
- Site 0047
-
-
Texas
-
Austin, Texas, Forenede Stater, 78754
- Ikke rekrutterer endnu
- Local Institution - 0049
-
Kontakt:
- Site 0049
-
Richardson, Texas, Forenede Stater, 75080
- Rekruttering
- Pillar Clinical Research - Richardson
-
Kontakt:
- Scott Bartley, Site 0133
- Telefonnummer: 214-396-4844
-
-
-
-
-
Poznan, Polen, 60-744
- Ikke rekrutterer endnu
- Local Institution - 0001
-
Kontakt:
- Site 0001
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 02-957
- Ikke rekrutterer endnu
- Local Institution - 0123
-
Kontakt:
- Site 0123
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, Polen, 15-272
- Ikke rekrutterer endnu
- Local Institution - 0122
-
Kontakt:
- Site 0122
-
-
-
-
-
Bucharest, Rumænien, 011241
- Ikke rekrutterer endnu
- Local Institution - 0174
-
Kontakt:
- Site 0174
-
Bucharest, Rumænien, 41914
- Ikke rekrutterer endnu
- Local Institution - 0106
-
Kontakt:
- Site 0106
-
Bucharest, Rumænien, 41914
- Ikke rekrutterer endnu
- Local Institution - 0109
-
Kontakt:
- Site 0109
-
-
Brăila County
-
Brașov, Brăila County, Rumænien, 500123
- Ikke rekrutterer endnu
- Local Institution - 0104
-
Kontakt:
- Site 0104
-
-
Bucharest
-
Bucharest, Bucharest, Rumænien, 041914
- Ikke rekrutterer endnu
- Local Institution - 0103
-
Kontakt:
- Site 0103
-
Bucharest, Bucharest, Rumænien, 041914
- Ikke rekrutterer endnu
- Local Institution - 0105
-
Kontakt:
- Site 0105
-
Bucharest, Bucharest, Rumænien, 041914
- Ikke rekrutterer endnu
- Local Institution - 0107
-
Kontakt:
- Site 0107
-
Bucharest, Bucharest, Rumænien, 041914
- Ikke rekrutterer endnu
- Local Institution - 0110
-
Kontakt:
- Site 0110
-
-
-
-
-
Valladolid, Spanien, 47012
- Ikke rekrutterer endnu
- Local Institution - 0167
-
Kontakt:
- Site 0167
-
Zamora, Spanien, 49021
- Ikke rekrutterer endnu
- Local Institution - 0181
-
Kontakt:
- Site 0181
-
-
Barcelona [Barcelona]
-
Barcelona, Barcelona [Barcelona], Spanien, 08003
- Ikke rekrutterer endnu
- Local Institution - 0112
-
Kontakt:
- Site 0112
-
-
-
-
-
Brno, Tjekkiet, 625 00
- Ikke rekrutterer endnu
- Local Institution - 0162
-
Kontakt:
- Site 0162
-
Klecany, Tjekkiet, 25067
- Ikke rekrutterer endnu
- Local Institution - 0014
-
Kontakt:
- Site 0014
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria
-
Participant must have a primary diagnosis of schizophrenia for at least 1 year established by a comprehensive psychiatric evaluation based on the DSM-5-TR (American Psychiatric Association 2022) criteria and confirmed by MINI for Psychotic Disorder Studies version 7.0.2 at screening.
-
Participant must have experienced hospitalization for schizophrenia within 1 year from the screening date.
-
Participant must be experiencing residual schizophrenia symptoms and have a PANSS total score ≥70 to ≤ 110 at screening and Day -1.
-
Participant much have a PANSS Score of ≥ 4 (moderate or greater) on ≥ 2 of the following Positive Scale (P) items at screening and Day -1:
- Item 1 (P1; delusions)
- Item 2 (P2; conceptual disorganization)
- Item 3 (P3; hallucinatory behavior)
- Item 6 (P6; suspiciousness/persecution)
-
Participant must have a CGI-S score of ≥ 4 at screening and Day -1
-
Participant must have a BMI ≥ 18 and ≤ 40 kg/m2.
Exclusion Criteria
- Participant must not have any primary DSM-5 disorder other than schizophrenia within 12 months before screening
- Participants must not have a newly diagnosed or are experiencing their first treated episode of psychosis or schizophrenia.
- Participant must not have a risk of suicidal behavior as determined by the Investigator's clinical assessment and/or Columbia-suicide Severity Rating Scale (C-SSRS).
- Participant must not have had psychiatric hospitalization(s) for more than 30 days (cumulative) within the 6 months before screening.
- Participant must not have a history of treatment resistance to schizophrenia medications
- Participant must not have decrease in PANSS total score (floor adjusted) between screening and Day -1 of more than 20%.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
Specified dose on specified days |
|
Eksperimentel: KarXT
|
Specified dose on specified days
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Time From Randomization to the First Relapse Event
Tidsramme: Up to approximately Week 43
|
Up to approximately Week 43
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Time to Discontinuation During Double-blind Treatment Period
Tidsramme: Approximately From Week 18 to 43
|
Approximately From Week 18 to 43
|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Up to approximately Week 45
|
Up to approximately Week 45
|
|
Number of Participants With Adverse Events of Special Interest (AESIs)
Tidsramme: Up to approximately Week 45
|
Up to approximately Week 45
|
|
Number of Participants With Procholinergic Symptoms
Tidsramme: Up to approximately Week 45
|
Up to approximately Week 45
|
|
Number of Participants With Anticholinergic Symptoms
Tidsramme: Up to approximately Week 45
|
Up to approximately Week 45
|
|
Number of Participants With Serious Adverse Events (SAEs)
Tidsramme: Up to approximately Week 45
|
Up to approximately Week 45
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studieleder: Bristol-Myers Squibb, Bristol-Myers Squibb
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CN012-0006
- 2025-523664-20 (Anden identifikator: EU CT Number)
- U1111-1327-7599 (Anden identifikator: WHO)
- 2025 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
IPD-delingstidsramme
See Plan Description
IPD-delingsadgangskriterier
See Plan Description
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .